Quarterly report pursuant to Section 13 or 15(d)

NON-CONTROLLING INTEREST

NON-CONTROLLING INTEREST

3 Months Ended

Mar. 31, 2022

NOTE 18 – NON-CONTROLLING INTEREST

On July 28, 2016, the Company formed BioCorRx Pharmaceuticals, Inc., a Nevada Corporation, for the purpose of developing certain business lines. In connection with the formation, the, the newly formed sub issued 24.2% ownership to current or former officers of the Company with the Company retaining 75.8%. From inception through December 31, 2017, there were no significant transactions. In 2018, BioCorRx Pharmaceuticals, Inc. began operations.

A reconciliation of the BioCorRx Pharmaceuticals, Inc. non-controlling loss attributable to the Company:

Net loss attributable to the non-controlling interest for the three months ended March 31, 2022:

Net loss	$	(2,276	)
Average Non-controlling interest percentage of profit/losses		24.2	%
Net loss attributable to the non-controlling interest	$	(551	)

The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2022:

Balance, December 31, 2021	$	(117,838	)
Net loss attributable to the non-controlling interest		(551	)
Balance, March 31, 2022	$	(118,389	)

Net loss attributable to the non-controlling interest for the three months ended March 31, 2021:

Net loss	$	(3,207	)
Average Non-controlling interest percentage of profit/losses		24.2	%
Net loss attributable to the non-controlling interest	$	(776	)

The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2021:

Balance, December 31, 2020	$	(115,454	)
Net loss attributable to the non-controlling interest		(776	)
Balance, March 31, 2021	$	(116,230	)